High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection

Oncologist

Volumn 15, Issue 7, 2010, Pages 732-743

  Jia, Jin Bin ^a   Wang, Wen Quan ^a   Sun, Hui Chuan ^a   Zhu, Xiao Dong ^a   Liu, Liang ^a   Zhuang, Peng Yuan ^a   Zhang, Ju Bo ^a   Zhang, Wei ^a   Xu, Hua Xiang ^a   Kong, Ling Qun ^a   Lu, Lu ^a   Wu, Wei Zhong ^a   Wang, Lu ^a   Tang, Zhao You ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Macrophage colony stimulating factor 1 receptor; Microenvironment; Peritumoral liver tissue; Prognosis

Indexed keywords

COLONY STIMULATING FACTOR 1 RECEPTOR; COLONY STIMULATING FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TISSUE MICROARRAY; TUMOR DIFFERENTIATION; TUMOR GROWTH; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; FEMALE; HEPATECTOMY; HUMANS; IMMUNOHISTOCHEMISTRY; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 77956097076     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0170     Document Type: Article

References (46)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002.CA Cancer J Clin 2005;55:74-108.
2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362:1907-1917.
3. Poon RT, Fan ST, Tsang FH et al. Locoregional therapies for hepatocellular carcinoma: A critical review from the surgeon's perspective. Ann Surg 2002;235:466-486.
4. Tang ZY, Ye SL, Liu YK et al. A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:187-196.
5. Ding Y, Chen B, Wang S et al. Overexpression of Tiam1 in hepatocellular carcinomas predicts poor prognosis of HCC patients. Int J Cancer 2009; 124:653-658.
6. Ye QH, Qin LX, Forgues M et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416-423.
7. Ke AW, Shi GM, Zhou J et al. Role of overexpression of CD151 and/or c-Met in predicting prognosis of hepatocellular carcinoma. Hepatology 2009;49:491-503.
8. Zhu XD, Zhang JB, Zhuang PY et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008;26:2707-2716.
9. Ju MJ, Qiu SJ, Fan J et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol 2009;131:498-510.
10. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359: 1995-2004.
11. Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10:99-111.
12. Rettenmier CW, Chen JH, Roussel MF et al. The product of the c-fms proto-oncogene: A glycoprotein with associated tyrosine kinase activity. Science 1985;228:320-322.
13. Wiktor-Jedrzejczak W, Gordon S. Cytokine regulation of the macrophage (M phi) system studied using the colony stimulating factor-1-deficient op/op mouse. Physiol Rev 1996;76:927-947.
14. Bartelmez SH, Stanley ER. Synergism between hemopoietic growth factors (HGFs) detected by their effects on cells bearing receptors for a lineage specific HGF: Assay of hemopoietin-1. J Cell Physiol 1985;122:370-378.
15. Suzumura A, Sawada M, Yamamoto H et al. Effects of colony stimulating factors on isolated microglia in vitro. J Neuroimmunol 1990;30:111-120.
16. Byrne PV, Guilbert LJ, Stanley ER. Distribution of cells bearing receptors for a colony-stimulating factor (CSF-1) in murine tissues. J Cell Biol 1981; 91:848-853.
17. Tushinski RJ, Oliver IT, Guilbert LJ et al. Survival of mononuclear phagocytes depends on a lineage-specific growth factor that the differentiated cells selectively destroy. Cell 1982;28:71-81.
18. Sapi E, Kacinski BM. The role of CSF-1 in normal and neoplastic breast physiology. Proc Soc Exp Biol Med 1999;220:1-8.
19. Ide H, Seligson DB, Memarzadeh S et al. Expression of colony-stimulating factor 1 receptor during prostate development and prostate cancer progression. Proc Natl Acad Sci USA 2002;99:14404-14409.
20. Dai XM, Ryan GR, Hapel AJ et al. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Blood 2002;99:111-120.
21. Woolford J, Rothwell V, Rohrschneider L. Characterization of the human c-fms gene product and its expression in cells of the monocyte-macrophage lineage. Mol Cell Biol 1985;5:3458-3466.
22. Sariban E, Mitchell T, Kufe D. Expression of the c-fms proto-oncogene during human monocytic differentiation. Nature 1985;316:64-66.
23. Zins K, Abraham D, SioudMet al. Colon cancer cell-derived tumor necrosis factor-alpha mediates the tumor growth-promoting response in macrophages by up-regulating the colony-stimulating factor-1 pathway. Cancer Res 2007;67:1038-1045.
24. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78.
25. Condeelis J, Pollard JW. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006;124:263-266.
26. Murray LJ, Abrams TJ, Long KR et al. SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003;20:757-766.
27. Scott DA, Aquila BM, Bebernitz GA et al. Pyridyl and thiazolyl bisamide CSF-1R inhibitors for the treatment of cancer. Bioorg Med Chem Lett 2008;18:4794-4797.
28. Wei S, Dai XM, Stanley ER. Transgenic expression of CSF-1 in CSF-1 receptor-expressing cells leads to macrophage activation, osteoporosis, and early death. J Leukoc Biol 2006;80:1445-1453.
29. Lin EY, Nguyen AV, Russell RG et al. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193:727-740.
30. Lin EY, Pollard JW. Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 2007;67:5064-5066.
31. Toy EP, Azodi M, Folk NL et al. Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor. Neoplasia 2009;11:136-144.
32. Kacinski BM, Scata KA, Carter D et al. FMS (CSF-1 receptor) and CSF-1 transcripts and protein are expressed by human breast carcinomas in vivo and in vitro. Oncogene 1991;6:941-952.
33. Kluger HM, Dolled-Filhart M, Rodov S et al. Macrophage colony-stimulating factor-1 receptor expression is associated with poor outcome in breast cancer by large cohort tissue microarray analysis. Clin Cancer Res 2004;10:173-177.
34. Richardsen E, Uglehus RD, Due J et al. The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma. Histopathology 2008;53:30-38.
35. Toy EP, Chambers JT, Kacinski BM et al. The activated macrophage colony-stimulating factor (CSF-1) receptor as a predictor of poor outcome in advanced epithelial ovarian carcinoma. Gynecol Oncol 2001;80:194-200.
36. Jia JB, Zhuang PY, Sun HC et al. Protein expression profiling of vascular endothelial growth factor and its receptors identifies subclasses of hepatocellular carcinoma and predicts survival. J Cancer Res Clin Oncol 2009; 135:847-854.
37. Sun HC, Zhang W, Qin LX et al. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma. J Hepatol 2007;47:684-690.
38. Qian YB, Zhang JB, Wu WZ et al. P48 is a predictive marker for outcomeof postoperative interferon-alpha treatment in patients with hepatitis B virus infection-related hepatocellular carcinoma. Cancer 2006;107:1562-1569.
39. Sun HC, Zhuang PY, Qin LX et al. Incidence and prognostic values of lymph node metastasis in operable hepatocellular carcinoma and evaluation of routine complete lymphadenectomy. J Surg Oncol 2007;96:37-45.
40. Gao Q, Qiu SJ, Fan J et al. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 2007;25:2586-2593.
41. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001;25:402-408.
42. Camp RL, Dolled-Filhart M, Rimm DL. X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res 2004;10:7252-7259.
43. Poon RT, Fan ST, Ng IO et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-507.
44. Kacinski BM. CSF-1 and its receptor in ovarian, endometrial and breast cancer. Ann Med 1995;27:79-85.
45. Dewhirst MW, Cao Y, Moeller B. Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 2008;8:425-437.
46. Patsialou A, Wyckoff J, Wang Y et al. Invasion of human breast cancer cells in vivo requires both paracrine and autocrine loops involving the colony-stimulating factor-1 receptor. Cancer Res 2009;69:9498-9506.